CoChat

Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California

Open access
Andrejko, Kristin L, Pry, Jake, Myers, Jennifer F, Jewell, Nicholas P, Openshaw, John, Watt, James, Jain, Seema, Lewnard, Joseph A, California COVID-19 Case-Control Study Team, Samani, Helia, Li, Sophia S, Barbaduomo, Camilla M, Walas, Nikolina, Wan, Christine, Fang, Anna T, Ho, Timothy, Tran, Vivian H, Xavier, Erin, Javadi, Mahsa H, Poindexter, Diana J, Dabbagh, Najla, Spinosa, Michelle M, Birkett, Nozomi, Frost, Paulina M, Dong, Zheng N, Saretha, Shrey, Cornejo, Adrian F, DeGuzman, Jennifer L, Bermejo, Miriam I, Park, Hyemin, Lam, Amanda · 2022 · Clinical Infectious Diseases
Cited by 46

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Background: Estimates of coronavirus disease 2019 (COVID-19) vaccine effectiveness under real-world conditions, and understanding of barriers to uptake, are necessary to inform vaccine rollout. Methods: We enrolled cases (testing positive) and controls (testing negative) from among the population whose SARS-CoV-2 molecular diagnostic test results from 24 February to 29 April 2021 were reported to the California Department of Public Health. Participants were matched on age, sex, and geographic region. We assessed participants’ self-reported history of mRNA-based COVID-19 vaccine receipt (BNT162b2 and mRNA-1273). Participants were considered fully vaccinated 2 weeks after second dose receipt. Among unvaccinated participants, we assessed willingness to receive vaccination. We measured vaccine effectiveness (VE) via the matched odds ratio of prior vaccination, comparing cases with controls. Results: We enrolled 1023 eligible participants aged ≥18 years. Among 525 cases, 71 (13.5%) received BNT162b2 or mRNA-1273; 20 (3.8%) were fully vaccinated with either product. Among 498 controls, 185 (37.1%) received BNT162b2 or mRNA-1273; 86 (16.3%) were fully vaccinated with either product. Two weeks after second dose receipt, VE was 87.0% (95% confidence interval: 68.6–94.6%) and 86.2% (68.4-93.9%) for BNT162b2 and mRNA-1273, respectively. Fully vaccinated participants receiving either product experienced 91.3% (79.3–96.3%) and 68.3% (27.9–85.7%) VE against symptomatic and asymptomatic infection, respectively. Among unvaccinated participants, 42.4% (159/375) residing in rural regions and 23.8% (67/281) residing in urban regions reported hesitancy to receive COVID-19 vaccination. Conclusions: Authorized mRNA-based vaccines are effective at reducing documented SARS-CoV-2 infections within the general population of California. Vaccine hesitancy presents a barrier to reaching coverage levels needed for herd immunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciab640

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 46

Metadata

Authors
Andrejko, K. L., Pry, J., Myers, J. F., Jewell, N. P., Openshaw, J., Watt, J., Jain, S., Lewnard, J. A., California COVID-19 Case-Control Study Team, Samani, H., Li, S. S., Barbaduomo, C. M., Walas, N., Wan, C., Fang, A. T., Ho, T., Tran, V. H., Xavier, E., Javadi, M. H., Poindexter, D. J., Dabbagh, N., Spinosa, M. M., Birkett, N., Frost, P. M., Dong, Z. N., Saretha, S., Cornejo, A. F., DeGuzman, J. L., Bermejo, M. I., Park, H., & Lam, A.
Venue
Clinical Infectious Diseases
Published
2021-07-20
Volume
74
Issue
8
Pages
1382-1389
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3185475792
Cited by
46
References
11
FWCI
3.11
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California. https://app.cochat.ai/papers/10.1093/cid/ciab640
The paper
Andrejko, K. L., Pry, J., Myers, J. F., Jewell, N. P., Openshaw, J., Watt, J., Jain, S., Lewnard, J. A., California COVID-19 Case-Control Study Team, Samani, H., Li, S. S., Barbaduomo, C. M., Walas, N., Wan, C., Fang, A. T., Ho, T., Tran, V. H., Xavier, E., Javadi, M. H., . . . Lam, A. (2022). Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab640

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.